DaVita
American dialysis provider / From Wikipedia, the free encyclopedia
DaVita Inc. provides kidney dialysis services through a network of 2,816 outpatient dialysis centers in the United States, serving 204,200 patients, and 321 outpatient dialysis centers in 10 other countries serving 3,200 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives unless they receive a donor kidney. The company has a 37% market share in the U.S. dialysis market. It is organized in Delaware and based in Denver.[2]
Company type | Public |
---|---|
NYSE: DVA S&P 500 component | |
Industry | Healthcare |
Founded | 1979; 45 years ago (1979) |
Headquarters | Denver, Colorado, United States |
Key people | Javier J. Rodriguez (CEO) Peter Grauer (lead independent director) |
Services | Dialysis |
Revenue | US$11.62 billion (2021) |
US$1.80 billion (2021) | |
US$978 million (2021) | |
Total assets | US$17.12 billion (2021) |
Total equity | US$756 million (2021) |
Owner | Berkshire Hathaway (37.9%)[1] |
Number of employees | 69,000 (2021) |
Website | davita |
Footnotes / references [2] |
In 2020, 68% of the company's revenues came from Medicare and other government-based health insurance programs. In 2020, 90% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 32% of revenues in 2020, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.[2]
The company is ranked 357th on the Fortune 500.[3]
The name "DaVita" was derived from the Italian language phrase "Dare Vita", which means "to give life".[4]